Gilead Stock News

(RTTNews) - Kite, a Gilead Company (GILD), said that yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma. The primary analysis of ZUMA-7, a global Phase 3 study evaluating Yescarta (axicabtagene ciloleucel) as a one-time infusion, in a

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL). Among all patients treated with Yescarta, the five-year overall survival (OS) rate was 42.6% (95% CI, 32.8 51.9). Among patients who had a complete response (CR), the five-year OS rate was 64.4% (95% CI, 50.8 75.1) and median survival time has

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced five-year follow-up data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult pa

Wall Street analysts forecast that Gilead Sciences, Inc. (NASDAQ:GILD) will report earnings per share of $1.45 for the current quarter, according to Zacks. Seven analysts have made estimates for Gilead Sciences earnings. The highest EPS estimate is $1.80 and the lowest is $1.21. Gilead Sciences reported earnings per share of $2.19 in the same quarter []

Gilead Sciences Inc. (NASDAQ:GILD)’s traded shares stood at 1.17 million during the latest session, with the company’s beta value hitting 0.35. At the last check today, the stock’s price was $69.91, to imply a decrease of -0.55% or -$0.39 in intraday trading. The GILD share’s 52-week high remains $73.34, putting it -4.91% down since that … There Has Been A -0.55% Decline For Gilead Sciences Inc. (NASDAQ: GILD). So What’s Next? Read More »

Gilead Sciences (GILD) closed the most recent trading day at $70.25, moving -0.07% from the previous trading session.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) have been given an average rating of “Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12-month price target among […]

Shoker Investment Counsel Inc. boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 12.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 12,837 shares of the biopharmaceutical companys stock after buying an additional 1,415 shares during the period. Shoker Investment Counsel Inc.s holdings []

Howland Capital Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,536 shares of the biopharmaceutical companys stock after selling 1,669 shares during the period. Howland Capital []

Dan Genter, CEO and chief investment officer at RNC Genter Capital, joins 'The Exchange' to discuss his top stock picks.

Plimoth Trust Co. LLC decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,505 shares of the biopharmaceutical companys stock after selling 747 shares during the period. Plimoth Trust Co. LLCs holdings []

Trial to evaluate antigen suppression combined with immunomodulation as a functional cure regimen for chronic HBV SAN FRANCISCO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (NASDAQ: VIR ) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating novel therapeutic combinations for the treatment of chronic hepatitis B virus (HBV) infection. The multi-arm trial, which is being conducted in collaboration with Gilead Sciences, Inc., is assessing various combinations of VIR-2218, Vir''s investigational small interfering ribonucleic acid (siRNA) that mediates RNA interference (RNAi); selgantolimod (GS-9688), Gilead Sciences'' investigational TLR-8 agonist; and nivolumab, an approved PD-1 inhibitor, in both nucleos(t)ide (NUC)-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate (TAF). "For the majority of patients with chronic HBV, a functional cure will likely require a sustained reduction in hepatitis B surface antigen and restoration of the immune response," said Carey Hwang, MD, PhD, senior vice president, clinical research, head of chronic infection for Vir Biotechnology. "We believe the combination of VIR-2218 and two immunomodulatory agents has the potential to improve the HBV-specific immune response and possibly achieve a functional cure.

Wells Fargo & Company began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research report released on Wednesday morning, The Fly reports. The firm issued an equal weight rating on the biopharmaceutical companys stock. A number of other brokerages have also recently issued reports on GILD. BMO Capital Markets upgraded Gilead Sciences from a []

We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S.

Investment analysts at Wells Fargo & Company began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a report released on Wednesday, The Fly reports. The firm set an equal weight rating on the biopharmaceutical companys stock. A number of other equities analysts also recently weighed in on the stock. Royal Bank of Canada reissued a []